1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - Abraxane: Nanoparticle Platform Delivers Improved Antitumor Activity"}],["$","meta","1",{"name":"description","content":"Presentation will be on development of nanoparticle albumin-bound (nab™) delivery platform and efficacy and safety advantages of first product, Abraxane (paclitaxel protein-bound particles) over conventionally formulated chemotherapeutic agents. Due in part to their small size, following IV administration the 130 nanometer particles quickly disperse as individual albumin molecules that then carry paclitaxel to the sites of tumor. The improved anti-tumor activity in metastatic breast cancer and a high level of activity in other cancers (including non-small cell lung cancer, malignant melanoma and head and neck cancers) is most likely due to the ability of Abraxane to take advantage of natural binding characteristics of albumin, endogenous albumin-mediated transport mechanisms and localization of albumin in areas of tumor due to binding to tumor-secreted proteins.\n
\n
\nhttp://nano.cancer.gov/events_nanotech_seminar_series.asp
"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - Abraxane: Nanoparticle Platform Delivers Improved Antitumor Activity"}],["$","meta","4",{"property":"og:description","content":"Presentation will be on development of nanoparticle albumin-bound (nab™) delivery platform and efficacy and safety advantages of first product, Abraxane (paclitaxel protein-bound particles) over conventionally formulated chemotherapeutic agents. Due in part to their small size, following IV administration the 130 nanometer particles quickly disperse as individual albumin molecules that then carry paclitaxel to the sites of tumor. The improved anti-tumor activity in metastatic breast cancer and a high level of activity in other cancers (including non-small cell lung cancer, malignant melanoma and head and neck cancers) is most likely due to the ability of Abraxane to take advantage of natural binding characteristics of albumin, endogenous albumin-mediated transport mechanisms and localization of albumin in areas of tumor due to binding to tumor-secreted proteins.\n
\n
\nhttp://nano.cancer.gov/events_nanotech_seminar_series.asp
"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/991b62c5-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/d95c53c9-5ac4-4ea8-86f5-c08389ae51bf.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - Abraxane: Nanoparticle Platform Delivers Improved Antitumor Activity"}],["$","meta","11",{"name":"twitter:description","content":"Presentation will be on development of nanoparticle albumin-bound (nab™) delivery platform and efficacy and safety advantages of first product, Abraxane (paclitaxel protein-bound particles) over conventionally formulated chemotherapeutic agents. Due in part to their small size, following IV administration the 130 nanometer particles quickly disperse as individual albumin molecules that then carry paclitaxel to the sites of tumor. The improved anti-tumor activity in metastatic breast cancer and a high level of activity in other cancers (including non-small cell lung cancer, malignant melanoma and head and neck cancers) is most likely due to the ability of Abraxane to take advantage of natural binding characteristics of albumin, endogenous albumin-mediated transport mechanisms and localization of albumin in areas of tumor due to binding to tumor-secreted proteins.\n
\n
\nhttp://nano.cancer.gov/events_nanotech_seminar_series.asp
"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}